Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

10 Years of Arthroscopic Latarjet Procedure: Outcome and Complications.

Meraner D, Smolen D, Sternberg C, Thallinger C, Hahne J, Leuzinger J.

Indian J Orthop. 2019 Jan-Feb;53(1):102-110. doi: 10.4103/ortho.IJOrtho_273_17.

2.

Non-Small Cell Lung Cancer in Countries of Central and Southeastern Europe: Diagnostic Procedures and Treatment Reimbursement Surveyed by the Central European Cooperative Oncology Group.

Ryska A, Buiga R, Fakirova A, Kern I, Olszewski W, Plank L, Seiwerth S, Toth E, Zivka E, Thallinger C, Zielinski C, Brcic L.

Oncologist. 2018 Dec;23(12):e152-e158. doi: 10.1634/theoncologist.2018-0008. Epub 2018 Aug 3.

PMID:
30076278
3.

Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Thallinger C, Füreder T, Preusser M, Heller G, Müllauer L, Höller C, Prosch H, Frank N, Swierzewski R, Berger W, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Feb;130(3-4):85-91. doi: 10.1007/s00508-017-1285-9. Epub 2017 Nov 2. Review.

4.

Educational video: the role of PD-L1 in the local tumour microenvironment.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2017 Feb 1;1(6):e000137. doi: 10.1136/esmoopen-2016-000137. eCollection 2016.

5.

CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology.

Preusser M, Berghoff AS, Thallinger C, Zielinski C.

ESMO Open. 2017 Jun 8;2(2):e000194. doi: 10.1136/esmoopen-2017-000194. eCollection 2017.

6.

Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2016 Apr 12;1(3):e000056. eCollection 2016.

7.

Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.

Thallinger C, Lang I, Kuhar CG, Bartsch R, Singer CF, Petruzelka L, Melichar B, Knittelfelder R, Brodowicz T, Zielinski C.

BMC Cancer. 2016 Feb 18;16:121. doi: 10.1186/s12885-016-2171-y.

8.

Management of bite wounds in children and adults-an analysis of over 5000 cases at a level I trauma centre.

Jaindl M, Oberleitner G, Endler G, Thallinger C, Kovar FM.

Wien Klin Wochenschr. 2016 May;128(9-10):367-75. doi: 10.1007/s00508-015-0900-x. Epub 2015 Dec 11.

PMID:
26659907
9.

Influence of adjunctive classical homeopathy on global health status and subjective wellbeing in cancer patients - A pragmatic randomized controlled trial.

Frass M, Friehs H, Thallinger C, Sohal NK, Marosi C, Muchitsch I, Gaertner K, Gleiss A, Schuster E, Oberbaum M.

Complement Ther Med. 2015 Jun;23(3):309-17. doi: 10.1016/j.ctim.2015.03.004. Epub 2015 Mar 23.

PMID:
26051564
10.

[Abscopal effect in the treatment of malignant melanoma].

Thallinger C, Prager G, Ringl H, Zielinski C.

Hautarzt. 2015 Jul;66(7):545-8. doi: 10.1007/s00105-014-3567-8. German.

PMID:
25576145
11.

Public perception of cancer care in Poland and Austria.

Jȩdrzejewski M, Thallinger C, Mrozik M, Kornek G, Zielinski C, Jassem J.

Oncologist. 2015 Jan;20(1):28-36. doi: 10.1634/theoncologist.2014-0226. Epub 2014 Dec 17.

12.

Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.

Haslik W, Hacker S, Felberbauer FX, Thallinger C, Bartsch R, Kornauth C, Deutschmann C, Mader RM.

Eur J Surg Oncol. 2015 Mar;41(3):378-85. doi: 10.1016/j.ejso.2014.11.042. Epub 2014 Dec 4.

PMID:
25515823
13.

Lack of correlation between blood group and HER-2 status in adenocarcinomas of the upper gastrointestinal tract.

Hejna M, Birner P, Preusser M, Thallinger CM, Worel N, Asari R, Dolak W, Schmid R, Schoppmann SF, Raderer M.

Mol Clin Oncol. 2013 Nov;1(6):1079-1083. Epub 2013 Sep 12.

14.

Long-term results of a nationwide general ultrasound screening system for developmental disorders of the hip: the Austrian hip screening program.

Thallinger C, Pospischill R, Ganger R, Radler C, Krall C, Grill F.

J Child Orthop. 2014 Feb;8(1):3-10. doi: 10.1007/s11832-014-0555-6. Epub 2014 Jan 22.

15.

Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma.

Thallinger CM, Kiesewetter B, Raderer M, Hejna M.

Anticancer Res. 2012 Nov;32(11):4609-27. Review.

PMID:
23155224
16.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14.

17.

The management of bite wounds in children--a retrospective analysis at a level I trauma centre.

Jaindl M, Grünauer J, Platzer P, Endler G, Thallinger C, Leitgeb J, Kovar FM.

Injury. 2012 Dec;43(12):2117-21. doi: 10.1016/j.injury.2012.04.016. Epub 2012 May 16.

PMID:
22607996
18.

Esophageal cancer: a critical evaluation of systemic second-line therapy.

Thallinger CM, Raderer M, Hejna M.

J Clin Oncol. 2011 Dec 10;29(35):4709-14. doi: 10.1200/JCO.2011.36.7599. Epub 2011 Nov 7. Review.

PMID:
22067408
19.

Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.

Maresch J, Schoppmann SF, Thallinger CM, Zielinski CC, Hejna M.

Crit Rev Oncol Hematol. 2012 Jun;82(3):310-22. doi: 10.1016/j.critrevonc.2011.06.003. Epub 2011 Jul 23. Review.

PMID:
21783379
20.
21.

New perspectives in stem cell research: beyond embryonic stem cells.

Leeb C, Jurga M, McGuckin C, Forraz N, Thallinger C, Moriggl R, Kenner L.

Cell Prolif. 2011 Apr;44 Suppl 1:9-14. doi: 10.1111/j.1365-2184.2010.00725.x. Review.

PMID:
21481037
22.

The ability of fluconazole to penetrate into ventilated, healthy and inflamed lung tissue in a model of severe sepsis in rats.

Mauric O, Thallinger C, Kugler SA, Joukhadar SM, Kovar FM, Konz KH, Graninger W, Joukhadar C.

Pharmacology. 2011;87(3-4):130-4. doi: 10.1159/000323738. Epub 2011 Feb 10.

PMID:
21502769
23.

Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.

Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, Egger G, Hassler MR, Thallinger C, Schmatz A, Turner SD, Greil R, Kenner L.

Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33. doi: 10.1073/pnas.1009719107. Epub 2010 Aug 30.

24.

The EGF 61A/G polymorphism - a predictive marker for recurrence of liver metastases from colorectal cancer.

Kovar FM, Thallinger C, Marsik CL, Perkmann T, Puhalla H, Haslacher H, Wrba F, Wagner OF, Gruenberger T, Endler G.

Wien Klin Wochenschr. 2009;121(19-20):638-43. doi: 10.1007/s00508-009-1250-3.

PMID:
19921131
25.

Multiple-dose pharmacokinetics of telithromycin in peripheral soft tissues.

Traunmüller F, Fille M, Thallinger C, Joukhadar C.

Int J Antimicrob Agents. 2009 Jul;34(1):72-5. doi: 10.1016/j.ijantimicag.2009.01.016. Epub 2009 Apr 19.

PMID:
19380214
26.

Concentrations of voriconazole in healthy and inflamed lung in rats.

Joukhadar C, Thallinger C, Pöppl W, Kovar F, Konz KH, Joukhadar SM, Traunmüller F.

Antimicrob Agents Chemother. 2009 Jun;53(6):2684-6. doi: 10.1128/AAC.00885-08. Epub 2009 Mar 30.

27.

Oral vs. bath PUVA using 8-methoxypsoralen for chronic palmoplantar eczema.

Tzaneva S, Kittler H, Thallinger C, Hönigsmann H, Tanew A.

Photodermatol Photoimmunol Photomed. 2009 Apr;25(2):101-5. doi: 10.1111/j.1600-0781.2009.00419.x.

PMID:
19292787
28.

Tigecycline has no effect on cytokine release in an ex vivo endotoxin model of human whole blood.

Traunmüller F, Thallinger C, Hausdorfer J, Lambers C, Tzaneva S, Kampitsch T, Endler G, Joukhadar C.

Int J Antimicrob Agents. 2009 Jun;33(6):583-6. doi: 10.1016/j.ijantimicag.2008.11.008. Epub 2009 Jan 25.

PMID:
19174323
29.

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.

Werzowa J, Cejka D, Fuereder T, Dekrout B, Thallinger C, Pehamberger H, Wacheck V, Pratscher B.

Br J Dermatol. 2009 May;160(5):955-64. doi: 10.1111/j.1365-2133.2008.08991.x. Epub 2008 Dec 16.

PMID:
19120326
30.

Orally administered rapamycin, dacarbazine or both for treatment of human melanoma evaluated in severe combined immunodeficiency mice.

Thallinger C, Skorjanec S, Soleiman A, Tzaneva S, Griss J, Rous W, Poeppl W, Weinlich G, Karimian-Teherani D, Joukhadar C.

Pharmacology. 2008;82(3):233-8. doi: 10.1159/000156490. Epub 2008 Sep 23.

PMID:
18810248
31.

Is experimental endotoxaemia in humans suitable for simulating antibiotic pharmacokinetics in sepsis and septic shock? A pilot study using the model compound fosfomycin.

Sauermann R, Mayer-Helm BX, Petsch M, Popovic M, Thallinger C, Joukhadar C.

Int J Antimicrob Agents. 2008 Mar;31(3):291-2. Epub 2007 Dec 21. No abstract available.

PMID:
18160265
32.

Characterization of NKIP: a novel, Na+/K+-ATPase interacting protein mediates neural differentiation and apoptosis.

Pratscher B, Friedrich C, Goger W, Allen M, Fink D, Thallinger C, Wolschek M, Frei K, Schöfer C, Pehamberger H, Wacheck V, Sorensen PH, Müller M, Jansen B, Lucas T.

Exp Cell Res. 2008 Feb 1;314(3):463-77. Epub 2007 Nov 24.

PMID:
18096156
33.

S-ibuprofen effectively inhibits thromboxane B2 levels and platelet function in an experimental model of lipopolysaccharide-stimulated and non-stimulated whole blood.

Kaehler S, Marsik C, Heinisch B, Thallinger C, Sauermann R, Kazemi-Shirazi L, Wagner O, Joukhadar C.

Pharmacology. 2008;81(2):181-6. Epub 2007 Nov 28.

PMID:
18043009
34.

Effect of severity of sepsis on tissue concentrations of linezolid.

Thallinger C, Buerger C, Plock N, Kljucar S, Wuenscher S, Sauermann R, Kloft C, Joukhadar C.

J Antimicrob Chemother. 2008 Jan;61(1):173-6. Epub 2007 Nov 13.

PMID:
17999976
35.

Daptomycin does not exert immunomodulatory effects in an experimental endotoxin model of human whole blood.

Thallinger C, Rothenburger M, Marsik C, Wuenscher S, Popovic M, Endler G, Wagner O, Joukhadar C.

Pharmacology. 2008;81(1):57-62. Epub 2007 Sep 11.

PMID:
17851272
36.

Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.

Thallinger C, Werzowa J, Poeppl W, Kovar FM, Pratscher B, Valent P, Quehenberger P, Joukhadar C.

J Invest Dermatol. 2007 Oct;127(10):2411-7. Epub 2007 May 17.

37.

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

Thallinger C, Poeppl W, Pratscher B, Mayerhofer M, Valent P, Tappeiner G, Joukhadar C.

Pharmacology. 2007;79(4):207-13. Epub 2007 Mar 22.

PMID:
17377418
38.

[Cytochrom-P450 mediated drug interactions caused by antibiotics].

Thallinger C, Joukhadar C.

Wien Med Wochenschr. 2006 Sep;156(17-18):508-14. Review. German.

PMID:
17041808
39.

The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.

Thallinger C, Urbauer E, Lackner E, Graselli U, Kostner K, Wolzt M, Joukhadar C.

Int J Clin Pharmacol Ther. 2005 Dec;43(12):551-7.

PMID:
16372516
40.

Wine ingestion has no effect on lipid peroxidation products.

Ziegler S, Kostner K, Thallinger C, Bur A, Brunner M, Wolzt M, Joukhadar C.

Pharmacology. 2005 Nov;75(3):152-6. Epub 2005 Sep 13.

PMID:
16166818
41.

Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.

Heere-Ress E, Boehm J, Thallinger C, Hoeller C, Wacheck V, Birner P, Wolff K, Pehamberger H, Jansen B.

J Invest Dermatol. 2005 Aug;125(2):201-6. Erratum in: J Invest Dermatol. 2005 Dec;125(6):1320.

42.

Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.

Skvara H, Thallinger C, Wacheck V, Monia BP, Pehamberger H, Jansen B, Selzer E.

Anticancer Res. 2005 Jul-Aug;25(4):2697-703.

43.

Clusterin regulates drug-resistance in melanoma cells.

Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wacheck V, Gleave ME, Pehamberger H, Jansen B.

J Invest Dermatol. 2005 Jun;124(6):1300-7.

44.

The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells.

Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, Heere-Ress E, Roka F, Sexl V, Pehamberger H.

J Invest Dermatol. 2005 Jun;124(6):1293-9.

45.

Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody.

Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H.

Int J Cancer. 2005 Apr 10;114(3):426-32.

46.

Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.

Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4185-91.

47.

The proto-oncoprotein c-Fos negatively regulates hepatocellular tumorigenesis.

Mikula M, Gotzmann J, Fischer AN, Wolschek MF, Thallinger C, Schulte-Hermann R, Beug H, Mikulits W.

Oncogene. 2003 Oct 2;22(43):6725-38.

PMID:
14555986
48.

Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells.

Wacheck V, Selzer E, Günsberg P, Lucas T, Meyer H, Thallinger C, Monia BP, Jansen B.

Br J Cancer. 2003 Oct 6;89(7):1352-7.

49.

Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes.

Pirker C, Holzmann K, Spiegl-Kreinecker S, Elbling L, Thallinger C, Pehamberger H, Micksche M, Berger W.

Melanoma Res. 2003 Oct;13(5):483-92.

PMID:
14512790
50.

Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.

Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Günsberg P, Polterauer P, Pehamberger H, Monia BP, Selzer E, Wolff K, Jansen B.

J Invest Dermatol. 2003 Jun;120(6):1081-6.

Supplemental Content

Loading ...
Support Center